PFC purchase complements previous deals for clinical research firms in the U.S.

Clinipace Worldwide is acquiring PFC Pharma Focus to expand its clinical research operations. Based in Zurich, with offices in Germany, Israel, and India, PFC is focused on drug and medical device development services and regulatory consulting.

With the addition of PFC, Clinipace will have centralized operations North American, South American, and European hubs for product development, clinical operations, data management, regulatory affairs, and GxP/CMC quality assurance.

Clinipace Worldwide’s European headquarters will be based in Zurich, with regional offices in Munich, Tel-Aviv, and New Delhi. The company will maintain its global headquarters in Research Triangle Park, NC, with additional domestic operations in Overland Park, KS, and Boulder, CO, as well as South American offices in Brazil, Argentina, and Peru. 

Commenting on the purchase of PFC, Jeff Williams, CEO and chairman, Clinipace Worldwide, says, “With this acquisition, our third in the past 18 months, we have assembled the right global footprint and the right mix of global therapeutic expertise, strategic product development assets, and operational capabilities to uniquely meet the needs of our clients. Together with the PFC team we’re better positioned to serve the needs of our clients by quickly and efficiently scaling to support their global Phase II/III trials across a number of therapeutic areas and indications.”

In March Clinipace boosted its regulatory services by buying Regulus Pharmaceutical Consulting, a regulatory affairs and quality assurance consultancy based in Boulder, CO. The company said that the deal increased its staff by 20%.

In October 2009, Clinipace closed its acquisition of Worldwide Clinical Research (WWCR), a Midwest-based company specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace changed its name to Clinipace Worldwide and added clinical operation expertise to its established data-management expertise.

With regard to PFC’s takeover, Kurt Pfister, former CEO of PFC, says, “This is a great win for our client base as they now have access to Clinipace’s extensive experience and capabilities in conducting trials and providing regulatory consulting across North and South America as well as their proven technology, the Tempo™ eClinical platform.” Pfister is now CEO of Clinipace Worldwide’s European operations.

Tempo is an integrated EDC and study management platform for clinical trials and registries. With this technology Clinipace Worldwide offers trial and registry services related to project management, site selection and patient recruitment, medical monitoring, data management (EDC-based), monitoring, site management, supply management, biostatistics, medical writing, IRB administration, safety surveillance, and regulatory guidance.

Previous articleThermo Fisher Scientific Purchases Sterilin for Single-Use Products
Next articleNorthwest Biotherapeutics Signs on Fraunhofer IZI for Brain Cancer Vaccine Development